Protalix Shares Fall Following Pfizer Deal
NEW YORK (AP) ¿ Shares of Protalix BioTherapeutics Inc. fell Tuesday as a newly announced licensing deal with Pfizer Inc. appeared to dispel hopes of a buyout.
Investors had been hoping Pfizer would make a move to buy Protalix. Instead, on Tuesday New York-based Pfizer licensed rights to a developing Gaucher's disease treatment, prompting a $60 million payment to Protalix.
"There were some expectations that it (Protalix) would be outright acquired," said Oppenheimer & Co. analyst Dr. Brian Abrahams. "But aspects of the collaboration itself are quite positive."
Protalix shares sank $1.09, or 11.1 percent, to $8.77 in afternoon trading. The stock has ranged from 96 cents to $12.50 over the past year.Under the deal, New York-based Pfizer will gain worldwide licensing rights to Protalix's taliglucerase alfa, or Uplyso, while Protalix retains exclusive commercialization rights in Israel, where the company is based. Taliglucerase alfa is an enzyme replacement therapy which has been designated an orphan drug by the Food and Drug Administration. Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. Incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV